Hedgehog pathway inhibitors market size to grow by USD 385.52 million from 2021 to 2026; Bristol Myers Squibb Co., Infinity Pharmaceuticals Inc., among others, identified as key vendors - Technavio

NEW YORK, April 12, 2023 /PRNewswire/ -- The hedgehog pathway inhibitors market size is forecasted to increase by USD 385.52 million from 2021 to 2026, at a CAGR of 13%, according to the recent market study by Technavio. The growth of the market will be driven by the high-risk factors for BCC and AML, the growth of the geriatric population, and increasing awareness about BCC and AML. Charts & data tables about market and segment sizes and forecast period (2022-2026) have been covered in this report. Download the Sample Report

Vendor Analysis

The global hedgehog pathway inhibitors market is concentrated. The competitive landscape of the market should witness the entry of a few new vendors during the forecast period. The challenge posed by the availability of substitutes is expected to play a significant role in the market; however, the introduction of patient assistance programs and the attractive industry growth rate should continue to be favorable factors for new vendors. Some of the key vendors covered in the report include:

• Bristol Myers Squibb Co. - The company offers hedgehog pathway inhibitor products such as patidegib.
• Inhibitor Therapeutics Inc - The company offers hedgehog pathway inhibitor products such as Erivedge.
• MAX BioPharma Inc. - The company offers hedgehog pathway inhibitor products such as SUBA-Itraconazole.
• Mayne Pharma Group Ltd. - The company offers hedgehog pathway inhibitor products such as Oxysterol Therapeutics.
• Infinity Pharmaceuticals Inc.
• F. Hoffmann La Roche Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• BridgeBio Pharma Inc.

Why Buy?

• Add credibility to strategy
• Analyzes competitor's offerings
• Get a holistic view of the market

Grow your profit margin with Technavio - Buy the Report

Key Benefits for Industry Players & Stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Get a holistic overview of the hedgehog pathway inhibitors market by industry experts to evaluate and develop growth strategies. Download the Sample

Market Segmentation:

The market is segmented by indication (BCC and AML) and geography (North America, Europe, Asia, and Rest of World (ROW)).

• By indication, the market growth in the BCC segment will be significant over the forecast period. The growth of the segment is driven by the increasing prevalence of Basal cell carcinoma (BCC) and the presence of various risk factors, such as exposure to UV radiation and chemicals and smoking. Changing lifestyles and the expansion of the geriatric population will also drive the growth of the segment.

Market Dynamics:

Key Drivers:

• High-risk factors for BCC and AML
• Growth of the geriatric population
• Increasing awareness about BCC and AML

The hedgehog pathway is largely associated with basal cell carcinoma (BCC) and acute myeloid leukemia (AML). There are many risk factors associated with the development of these diseases. Some of the major risk factors include exposure to UV radiation from sunlight or indoor tanning, a history of skin cancer, chronic infections and skin inflammations, smoking, and others. For instance, when smoking, tobacco smoke is absorbed by the lungs and spread through the bloodstream to many parts of the body. With the increased consumption of tobacco products, the prevalence of AML is increasing worldwide. For instance, every year, the US spends nearly USD 170 billion on medical care to treat smoking-related diseases in adults. The availability of such high-risk factors is increasing the prevalence of BCC and AML. All these factors are expected to drive the growth of the market.

Major Trends:

• Development of repurposed formulations
• Strategic alliances
• Funding for cancer-related research

The lack of approved hedgehog pathway inhibitors has created a huge unmet need for safe and effective hedgehog pathway inhibitors. This has driven many vendors to develop repurposed drug formulations to overcome challenges associated with clinical development. For instance, Inhibitor Therapeutics Inc., formerly known as HedgePath Pharmaceuticals Inc., in collaboration with Mayne Pharma Group Ltd., developed a repurposed formulation of itraconazole, namely SUBA-Itraconazole. SUBA technology enhances the bioavailability of poorly soluble approved drugs. It increases bioavailability, reduces intra-patient/inter-patient variability, and lowers side effects. The introduction of such repurposed formulations will positively influence market growth.

Key Challenges:

• Availability of substitutes
• Clinical trial failures of hedgehog pathway inhibitors
• Drug resistance

The availability of substitutes is one of the major challenges hindering the growth of the market. There are several alternative pharmacologic and procedural treatments for the treatment of AML and BCC. Chemotherapy, immune-checkpoint inhibitors, tyrosine kinase inhibitors, and procedural treatments such as cryotherapy (cryosurgery), photodynamic therapy, laser surgery, chemical peeling, and radiation therapy are available for the treatment of BCC and AML. Laser surgery is another alternative option, in which a beam of laser light is used to vaporize the cancerous cells. The availability of such alternatives will reduce the growth potential of the market.

Gain instant access to 17,000+ market research reports. 
Technavio's SUBSCRIPTION platform

What are the key data covered in this hedgehog pathway inhibitors market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the hedgehog pathway inhibitors market between 2022 and 2026
• Precise estimation of the size of the hedgehog pathway inhibitors market and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the hedgehog pathway inhibitors market industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of hedgehog pathway inhibitors market vendors

Related Reports:

• The proteasome inhibitors market size is expected to grow by USD 2.20 billion from 2021 to 2026. The huge unmet need is notably driving the proteasome inhibitors market growth, although factors such as the threat from biologics may impede the market growth.
• The BRAF kinase inhibitors market size is expected to accelerate at a CAGR of 7.73% and grow by USD 1.19 billion from 2021 to 2026. The high target affinity and specificity of BRAF kinase inhibitors are notably driving the BRAF kinase inhibitors market growth, although factors such as the availability of substitute therapies may impede market growth.

Browse through Technavio's Health Care Market Reports

Table of contents:

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Indication
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Indication

• 5.1 Market segments
• Exhibit 24: Chart on Indication - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Indication - Market share 2021-2026 (%)

• 5.2 Comparison by Indication 
• Exhibit 26: Chart on Comparison by Indication
• Exhibit 27: Data Table on Comparison by Indication

• 5.3 BCC - Market size and forecast 2021-2026 
• Exhibit 28: Chart on BCC - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on BCC - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on BCC - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on BCC - Year-over-year growth 2021-2026 (%)

• 5.4 AML - Market size and forecast 2021-2026 
• Exhibit 32: Chart on AML - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on AML - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on AML - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on AML - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Indication 
• Exhibit 36: Market opportunity by Indication ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026 
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026 
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026 
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026 
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Canada - Market size and forecast 2021-2026 
• Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.9 Germany - Market size and forecast 2021-2026 
• Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.10 UK - Market size and forecast 2021-2026 
• Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.11 China - Market size and forecast 2021-2026 
• Exhibit 74: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography 
• Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 79: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 81: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 82: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 83: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 84: Matrix on vendor position and classification

• 10.3 BridgeBio Pharma Inc. 
• Exhibit 85: BridgeBio Pharma Inc. - Overview
• Exhibit 86: BridgeBio Pharma Inc. - Product / Service
• Exhibit 87: BridgeBio Pharma Inc. - Key news
• Exhibit 88: BridgeBio Pharma Inc. - Key offerings

• 10.4 Bristol Myers Squibb Co. 
• Exhibit 89: Bristol Myers Squibb Co. - Overview
• Exhibit 90: Bristol Myers Squibb Co. - Product / Service
• Exhibit 91: Bristol Myers Squibb Co. - Key offerings

• 10.5 F. Hoffmann La Roche Ltd. 
• Exhibit 92: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 93: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 94: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 95: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 96: F. Hoffmann La Roche Ltd. - Segment focus

• 10.6 Inhibitor Therapeutics Inc 
• Exhibit 97: Inhibitor Therapeutics Inc - Overview
• Exhibit 98: Inhibitor Therapeutics Inc - Product / Service
• Exhibit 99: Inhibitor Therapeutics Inc - Key offerings

• 10.7 MAX BioPharma Inc.
• Exhibit 100: MAX BioPharma Inc. - Overview
• Exhibit 101: MAX BioPharma Inc. - Product / Service
• Exhibit 102: MAX BioPharma Inc. - Key offerings

• 10.8 Mayne Pharma Group Ltd. 
• Exhibit 103: Mayne Pharma Group Ltd. - Overview
• Exhibit 104: Mayne Pharma Group Ltd. - Business segments
• Exhibit 105: Mayne Pharma Group Ltd. - Key news
• Exhibit 106: Mayne Pharma Group Ltd. - Key offerings
• Exhibit 107: Mayne Pharma Group Ltd. - Segment focus

• 10.9 Novartis AG
• Exhibit 108: Novartis AG - Overview
• Exhibit 109: Novartis AG - Business segments
• Exhibit 110: Novartis AG - Key offerings
• Exhibit 111: Novartis AG - Segment focus

• 10.10 Pfizer Inc.
• Exhibit 112: Pfizer Inc. - Overview
• Exhibit 113: Pfizer Inc. - Product / Service
• Exhibit 114: Pfizer Inc. - Key news
• Exhibit 115: Pfizer Inc. - Key offerings

• 10.11 Sanofi
• Exhibit 116: Sanofi - Overview
• Exhibit 117: Sanofi - Business segments
• Exhibit 118: Sanofi - Key news
• Exhibit 119: Sanofi - Key offerings
• Exhibit 120: Sanofi - Segment focus

• 10.12 Sun Pharmaceutical Industries Ltd. 
• Exhibit 121: Sun Pharmaceutical Industries Ltd. - Overview
• Exhibit 122: Sun Pharmaceutical Industries Ltd. - Product / Service
• Exhibit 123: Sun Pharmaceutical Industries Ltd. - Key offerings

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 124: Inclusions checklist
• Exhibit 125: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 126: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 127: Research methodology
• Exhibit 128: Validation techniques employed for market sizing
• Exhibit 129: Information sources

• 11.5 List of abbreviations 
• Exhibit 130: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio